Empagliflozin Provides Kidney Protection and Heart Failure Risk Reduction in Acute Myocardial Infarction Patients
Empagliflozin shows promise in protecting kidney function and reducing heart failure risk in patients after acute myocardial infarction, according to recent research.
Recent research published in Nature Cardiovascular Research highlights the beneficial effects of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, in patients experiencing acute myocardial infarction (MI). The study analyzed data from a multicenter clinical trial involving 6,522 patients at risk for heart failure, assessing the drug's impact on kidney function and cardiovascular outcomes.
The findings reveal that empagliflozin helps preserve kidney function over a 24-month period, as indicated by stable estimated glomerular filtration rates (eGFR), contrasting with a decline observed in the placebo group. This kidney-protective effect was consistent regardless of baseline kidney health, demonstrating empagliflozin's broad applicability.
Moreover, patients treated with empagliflozin experienced a significant reduction in heart failure admissions and all-cause mortality, underscoring its cardiovascular benefits. Importantly, the study confirmed that initiating empagliflozin shortly after an acute MI was safe, with comparable short-term adverse event rates between treatment groups.
The study was led by Rahul Aggarwal, M.D., from Harvard Medical School, with safety and efficacy data supported by the pharmaceutical companies Boehringer Ingelheim and Eli Lilly. These results suggest that empagliflozin not only aids in managing blood sugar levels but also offers vital renal and cardiovascular protection during the critical recovery phase after a heart attack.
This evidence supports the integration of empagliflozin into treatment protocols for acute MI patients, highlighting its potential to improve long-term outcomes through kidney preservation and heart failure risk reduction.
For more details, see the original publication at: https://www.nature.com/articles/s44161-025-00657-7.
_source: https://medicalxpress.com/news/2025-06-empagliflozin-kidney-effects-acute-myocardial.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Zebrafish Model Unveils Potential Drugs for Rare Genetic Disease XMEA
A zebrafish model of the ultra-rare genetic disorder XMEA has led to the discovery of two promising drug candidates that may offer new hope for affected patients.
'Closed loop' learning barriers hinder the use of bedside ultrasound by clinicians
Systemic barriers and workplace cultures are preventing clinicians from fully utilizing bedside ultrasound technology, potentially missing life-saving diagnoses. A new study explores strategies to overcome these challenges and improve patient care.
Australia's Leading Pharmaceutical Companies Urged to Reduce Carbon Emissions
Australian pharmaceutical companies are being called to action to significantly reduce their carbon emissions and embrace sustainable practices to combat climate change and meet regulatory standards.